XTX Topco Ltd Purchases 167,854 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

XTX Topco Ltd raised its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1,581.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 178,465 shares of the company’s stock after purchasing an additional 167,854 shares during the quarter. XTX Topco Ltd’s holdings in Zentalis Pharmaceuticals were worth $730,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Rafferty Asset Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 79.4% in the 4th quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock worth $5,456,000 after acquiring an additional 159,439 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at $606,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $680,000. Finally, Decheng Capital LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $31,809,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZNTL shares. Stifel Nicolaus dropped their target price on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, June 18th. UBS Group cut shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $28.00 to $5.00 in a research report on Thursday, June 20th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a report on Monday, August 12th. Morgan Stanley reissued an “equal weight” rating and issued a $8.00 target price (down from $38.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.78.

Zentalis Pharmaceuticals Stock Down 3.2 %

NASDAQ:ZNTL opened at $4.22 on Monday. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.83 and a 12-month high of $22.70. The stock’s fifty day simple moving average is $3.56 and its 200-day simple moving average is $8.32. The firm has a market capitalization of $299.73 million, a P/E ratio of -1.27 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period in the previous year, the company posted ($1.85) earnings per share. As a group, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.95 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.